Ascentage Pharma Group International announced that Mr. Zhu Yifei will succeed Mr. Zhu Gang as the Chief Commercial Officer, who will be fully responsible for the company's commercial operations and will report to Dr. Yang Dajun, Chairman and Chief Executive Officer (CEO). Mr. Zhu Gang plans to retire in September 2023. During the transition period, he will assist Dr. Yang Dajun and Mr. Zhu Yifei to jointly promote the commercialization process as a company consultant.

Mr. Zhu Yifei graduated from the School of Medicine of Zhejiang University. He has been working in the pharmaceutical field for more than 20 years and has extensive commercialization experience. Oncology, immunotherapy, skin, infection and central nervous system, etc., and has extensive commercialization experience in the field of hematological tumors, and was responsible for the commercialization of multiple myeloma, chronic lymphocytic leukemia and other therapeutic areas.

He has profound accumulation in multinational companies, local pharmaceutical companies and innovative drug companies, and has made remarkable achievements in building and expanding commercialization teams and promoting the implementation of commercialization strategies.